Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DRUG
DRUG
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DRUG News
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
4d ago
Newsfilter
B Group Acquires New Stake in Bright Minds Biosciences
May 21 2026
Fool
B Group Acquires Stake in Bright Minds Biosciences
May 21 2026
NASDAQ.COM
B Group Acquires Stake in Bright Minds Biosciences
May 21 2026
Yahoo Finance
Bright Minds Biosciences Reports Q1 2026 Financial Results
May 20 2026
seekingalpha
Drug Farm Reveals FDA Acceptance of DF-003 into Rare Disease Evidence Principles Process for Rosah Syndrome
Mar 05 2026
moomoo
H.C. Wainwright Increases Target Price for Bright Minds Biosciences Inc. to $145, Up from $115
Mar 04 2026
moomoo
Bright Minds Biosciences to Present at Multiple Healthcare Conferences
Feb 25 2026
Newsfilter
Bright Minds Biosciences Prices 1.945M Shares at $90 for $175.05M Offering
Jan 08 2026
Globenewswire
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
Jan 07 2026
Benzinga
Bright Minds Biosciences Launches $100 Million Public Offering
Jan 07 2026
Benzinga
Barclays Cuts BJ's Wholesale Price Target to $90
Jan 07 2026
Benzinga
Bright Minds Reports Phase 2 BREAKTHROUGH Trial Results for BMB-101, 73.1% Seizure Reduction
Jan 06 2026
Benzinga
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Bright Minds' BMB-101 Shows Significant Seizure Reduction in Phase 2 Trial
Jan 06 2026
Globenewswire
Bright Minds Biosciences to Report Phase 2 BMB-101 Results on January 6, 2026
Jan 06 2026
NASDAQ.COM
Show More News
